Hif1a Cancer Research Results

Hif1a, HIF1α/HIF1a: Click to Expand ⟱
Source:
Type:
Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.
CRC, Colorectal Cancer: Click to Expand ⟱
Colorectal cancer is a broader term that encompasses both colon and rectal cancer.
Scientific Papers found: Click to Expand⟱
4774- 5-FU,  TQ,  CoQ10,    Exploring potential additive effects of 5-fluorouracil, thymoquinone, and coenzyme Q10 triple therapy on colon cancer cells in relation to glycolysis and redox status modulation
- in-vitro, CRC, NA
AntiCan↑, TumCCA↑, Apoptosis↑, eff↑, Bcl-2↓, survivin↓, P21↑, p27↑, BAX↑, Cyt‑c↑, Casp3↑, PI3K↓, Akt↓, mTOR↓, Hif1a↓, PTEN↑, AMPKα↑, PDH↑, LDHA↓, antiOx↓, ROS↑, AntiCan↑,
4561- AgNPs,  VitC,    Cellular Effects Nanosilver on Cancer and Non-cancer Cells: Potential Environmental and Human Health Impacts
- in-vitro, CRC, HCT116 - in-vitro, Nor, HEK293
NRF2↑, TumCCA↑, ROS↑, selectivity↑, *AntiViral↑, *toxicity↝, ETC↓, MMP↓, DNAdam↑, Apoptosis↑, lipid-P↑, other↝, UPR↑, *GRP78/BiP↑, *p‑PERK↑, *cl‑eIF2α↑, *CHOP↑, *JNK↑, Hif1a↓, AntiCan↑, *toxicity↓, eff↑,
5398- Ash,    Withaferin-A inhibits colorectal cancer growth and metastasis by targeting the HSP90/HIF-1α/EMT axis
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
TumCG↓, TumCMig↓, TumCI↓, HSP90↓, Hif1a↓, EMT↓,
2708- BBR,    Berberine decelerates glucose metabolism via suppression of mTOR‑dependent HIF‑1α protein synthesis in colon cancer cells
- in-vitro, CRC, HCT116
TumCG↓, GlucoseCon↓, GLUT1↓, LDHA↓, HK2↓, Hif1a↓, mTOR↓, Glycolysis↓,
811- GAR,    Garcinol exhibits anti-proliferative activities by targeting microsomal prostaglandin E synthase-1 in human colon cancer cells
- in-vitro, CRC, HT-29
mPGES-1↓, Hif1a↓, VEGF↓, CXCR4↓, MMP2↓, MMP9↓, Casp3↑, TumCP↓, PGE2↓,
3081- RES,    Resveratrol and p53: How are they involved in CRC plasticity and apoptosis?
- Review, CRC, NA
NF-kB↓, FAK↓, Ki-67↓, MMP9↓, CSCs↓, CD44↓, CD133↓, ALDH1A1↓, EMT↓, ChemoSen↑, Hif1a↓, ITGB1↓, Inflam↓,
3064- RES,    Resveratrol Suppresses Cancer Cell Glucose Uptake by Targeting Reactive Oxygen Species–Mediated Hypoxia-Inducible Factor-1α Activation
- in-vitro, CRC, HT-29 - in-vitro, BC, T47D - in-vitro, Lung, LLC1
FDG↓, ROS↓, Hif1a↓, GLUT1↓, lactateProd↓,
3036- RosA,    Anti-Warburg effect of rosmarinic acid via miR-155 in colorectal carcinoma cells
- in-vitro, CRC, HCT8 - in-vitro, CRC, HCT116 - in-vitro, CRC, LS174T
GlucoseCon↓, lactateProd↓, Hif1a↓, Inflam↓, miR-155↓, STAT3↓, Glycolysis↓, IL6↓, Warburg↓,
963- SFN,    Sulforaphane inhibits hypoxia-induced HIF-1α and VEGF expression and migration of human colon cancer cells
- in-vitro, CRC, HCT116 - in-vitro, GC, AGS
Hif1a↓, VEGF↓, angioG↓, Akt∅, ERK∅,
965- SK,    Shikonin suppresses proliferation and induces cell cycle arrest through the inhibition of hypoxia-inducible factor-1α signaling
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW-620
Hif1a↓, ROS↓, mTOR↓, p70S6↓, 4E-BP1↓, eIF2α↓, TumCCA↑, TumCP↓, Half-Life↝,
3431- TQ,    PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer
- in-vitro, CRC, HCT116 - in-vitro, CRC, SW48
Glycolysis↓, Warburg↓, HK2↓, ATP↓, NADPH↓, PI3K↓, Akt↓, TumCP↓, E-cadherin↑, N-cadherin↓, Hif1a↓, PKM2↓, GlucoseCon↓, lactateProd↓, EMT↓,
1067- VitC,    Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer
- in-vivo, CRC, NA
PDK1↓, Hif1a↓, GLUT1↓, ATP↓, MMP↓,

Showing Research Papers: 1 to 12 of 12

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 12

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   lipid-P↑, 1,   NRF2↑, 1,   ROS↓, 2,   ROS↑, 2,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 2,   ETC↓, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis ⓘ

FDG↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 3,   HK2↓, 2,   lactateProd↓, 3,   LDHA↓, 2,   NADPH↓, 1,   PDH↑, 1,   PDK1↓, 1,   PKM2↓, 1,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 2,   Akt∅, 1,   Apoptosis↑, 2,   BAX↑, 1,   Bcl-2↓, 1,   Casp3↑, 2,   Cyt‑c↑, 1,   p27↑, 1,   survivin↓, 1,  

Kinase & Signal Transduction ⓘ

AMPKα↑, 1,   p70S6↓, 1,  

Transcription & Epigenetics ⓘ

other↝, 1,  

Protein Folding & ER Stress ⓘ

eIF2α↓, 1,   HSP90↓, 1,   UPR↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,  

Cell Cycle & Senescence ⓘ

P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

4E-BP1↓, 1,   ALDH1A1↓, 1,   CD133↓, 1,   CD44↓, 1,   CSCs↓, 1,   EMT↓, 3,   ERK∅, 1,   mTOR↓, 3,   PI3K↓, 2,   PTEN↑, 1,   STAT3↓, 1,   TumCG↓, 2,  

Migration ⓘ

E-cadherin↑, 1,   FAK↓, 1,   ITGB1↓, 1,   Ki-67↓, 1,   miR-155↓, 1,   MMP2↓, 1,   MMP9↓, 2,   N-cadherin↓, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCP↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   Hif1a↓, 12,   VEGF↓, 2,  

Barriers & Transport ⓘ

GLUT1↓, 3,  

Immune & Inflammatory Signaling ⓘ

CXCR4↓, 1,   IL6↓, 1,   Inflam↓, 2,   mPGES-1↓, 1,   NF-kB↓, 1,   PGE2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 2,   Half-Life↝, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,   Ki-67↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 3,  
Total Targets: 77

Pathway results for Effect on Normal Cells:


Cell Death ⓘ

JNK↑, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   cl‑eIF2α↑, 1,   GRP78/BiP↑, 1,   p‑PERK↑, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,   toxicity↝, 1,  

Infection & Microbiome ⓘ

AntiViral↑, 1,  
Total Targets: 8

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a
2 Thymoquinone
2 Vitamin C (Ascorbic Acid)
2 Resveratrol
1 5-fluorouracil
1 Coenzyme Q10
1 Silver-NanoParticles
1 Ashwagandha(Withaferin A)
1 Berberine
1 Garcinol
1 Rosmarinic acid
1 Sulforaphane (mainly Broccoli)
1 Shikonin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:6  Cells:%  prod#:%  Target#:143  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page